Enhanced oral activity response to A77636 in neonatal 6-hydroxydopamine-lesioned rats.
Enhanced oral activity response to A77636 in neonatal 6-hydroxydopamine-lesioned rats.
复制标题
新生 6-羟基多巴胺损伤大鼠对 A77636 的口腔活动反应增强。
DOI：
10.1016/0014-2999(94)90771-4
复制
发表时间：
1994
影响因子：
5
通讯作者：
Kostrzewa,RM
中科院分区：
文献类型：
--
作者：
Huang,NY;Kostrzewa,RM
To study the role of dopamine D1receptors in enhanced oral activity effects of SKF 38393 ((±)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol) in neonatal 6-hydroxydopamine-lesioned rats, SKF 38393 was compared to the full agonist, A77636 ((1R,3S)-3-(1′-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran). At 3 days after birth rats were treated with 6-hydroxydopamine HBr (200 μg, salt form, i.c.v.; desipramine (20 mg/kg i.p.), 1 h) or vehicle. At 6–8 months a 0.01 mg/kg dose of A77636 HCl increased oral activity in 6-hydroxydopamine vs. control rats (P< 0.01). A77636 and SKF 38393 produced identical maximal responses of 35–36 oral movements at 0.1 and 1.0 mg/kg, respectively. SCH 23390 (R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine) HCl (0.3 mg/kg i.p.) attenuated the response to A77636. Neither A77636 HCl (0.01–1.0 mg/kg i.p.) nor SKF 38393 HCl (0.03–3.0 mg/kg i.p.) induced oral activity in intact rats. The findings demonstrate that A77636 is more potent than SKF 38393, and that supersensitized dopamine D1receptors are involved in the induction of oral behavior in neonatal 6-hydroxydopamine-lesioned rats.
